دورية أكاديمية

Development of a subunit vaccine containing recombinant Riemerella anatipestifer outer membrane protein A and CpG ODN adjuvant.

التفاصيل البيبلوغرافية
العنوان: Development of a subunit vaccine containing recombinant Riemerella anatipestifer outer membrane protein A and CpG ODN adjuvant.
المؤلفون: Chu, Chun-Yen1, Liu, Chia-Hui1, Liou, Jhong-Jie1, Lee, Jai-Wei2, Cheng, Li-Ting1 chenglt@mail.npust.edu.tw
المصدر: Vaccine. Jan2015, Vol. 33 Issue 1, p92-99. 8p.
مصطلحات موضوعية: *GRAM-negative bacterial diseases, *BACTERIAL cell walls, *MEMBRANE proteins, *BACTERIAL vaccines, *CPG nucleotides, *SEPSIS, *DUCKS, *DISEASES
مستخلص: Riemerella anatipestifer , a Gram-negative bacillus, causes septicemia that can result in high mortality for ducklings. In this study, we evaluated the immune response and protective efficacy provided by a subunit vaccine containing recombinant outer membrane protein A (rOmpA) and plasmid constructs containing CpG oligodeoxynucleotides (ODN). Results showed that CpG ODN enhanced both humoral and cell-mediated immunity elicited by rOmpA as early as two weeks after primary immunization. When compared to ducks immunized with rOmpA, ducks immunized with rOmpA + CpG ODN showed higher levels ( p < 0.05) of antibody titer, T cell proliferation, and percentages of CD4 + and CD8 + T cell in peripheral blood mononuclear cells (PBMCs). The relative fold inductions of mRNA expression of Th1-type (IFN-γ and IL-12), and Th2-type (IL-6) cytokines in PBMCs isolated from ducks immunized with rOmpA + CpG ODN were significantly higher than those of the rOmpA group. Homologous challenge result showed that the rOmpA + CpG ODN vaccine reduced the pathological score by 90% in comparison with the saline control. In conclusion, our study found that CpG ODN can enhance both humoral and cellular immunity elicited by a rOmpA vaccine. The rOmpA + CpG ODN vaccine can be further developed as a subunit vaccine against R. anatipestifer . [ABSTRACT FROM AUTHOR]
قاعدة البيانات: Academic Search Index
الوصف
تدمد:0264410X
DOI:10.1016/j.vaccine.2014.11.010